Pain and quality of life in patients with acute duodenal ulcer treated with ranitidine
Authors:
- 1 August 1995
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 9 (4) , 433-439
Abstract
SUMMARY: Background: The various components of pain and quality of life in duodenal ulcer patients receiving antisecretory drugs have not been studied to date. Methods: Ninety‐five patients with epigastric pain and duodenal ulcer at endoscopy completed this prospective, multicenter, open‐study. All were treated with effervescent ranitidine 300 mg daily for 4 weeks. The following parameters were assessed: (a) disappearance of duodenal ulcer pain by self‐evaluation and on a weekly visual analogue scale (VAS) from 0 to 100; (b) evolution of sensory and affective components of ulcer pain by the Validated French Version of the McGill Pain Questionnaire (Questionnaire Douleur de Saint‐Antoine, QDSA); (c) quality of life by the Nottingham Health Profile (NHP) which includes six criteria: pain, mobility, energy, emotions, sleep and social isolation. Results: Forty‐nine, 66 and 87% of the patients were pain‐free during the day‐time after 7, 14 and 28 days, respectively. Corresponding figures for the night‐time were 80%, 88% and 97% respectively. Median time to disappearance of ulcer pain was 8 days. VAS self‐assessment showed a significant decrease each week throughout the treatment period (P= 0.001). Sensory and affective QDSA scores were significantly improved after the second day and at each assessment during the 28 days of treatment (P= 0.001). Physical as well as affective aspects of quality of life were significantly improved after 28 days for each of the six criteria explored (P= 0.001). The duodenal ulcer healing rate was 86% after 4 weeks of treatment. Conclusions: Using complementary scales measuring different aspects of ulcer pain, sensory and affective components improved significantly from the second day of treatment with ranitidine 300 mg. A significant improvement in quality of life is observed after a 4‐week treatment.QDSA and NHP appear to be useful evaluation tools of duodenal ulcer pain and quality of life.Keywords
This publication has 15 references indexed in Scilit:
- Comparative study of the validity of four French McGill Pain Questionnaire (MPQ) versionsPain, 1992
- Ranitidine in the treatment of duodenal ulcer disease: relationship between antisecretory effect and ulcer healing rateAlimentary Pharmacology & Therapeutics, 1991
- Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidineGastroenterology, 1990
- The French version of the Nottingham health profile. A comparison of items weights with those of the source versionSocial Science & Medicine, 1990
- Silent Peptic Ulceration: Deadly Silence or Golden Silence?Gastroenterology, 1989
- Joint pain and quality of life; results of a randomised trial.British Journal of Clinical Pharmacology, 1989
- DOES MAINTENANCE THERAPY KEEP DUODENAL ULCERS HEALED?The Lancet, 1988
- Acute treatment of duodenal ulcer: a multicentre study to compare ranitidine 150 mg twice daily with ranitidine 300 mg once at night.Gut, 1986
- Uncontrolled factors in controlled trials of peptic ulcerDigestive Diseases and Sciences, 1984
- The McGill Pain Questionnaire: Major properties and scoring methodsPain, 1975